Aor Vinpo 15 - 90 Veg Capsules

AOR Vinpo 15 - 90 Veg Capsules:

Supports Optimal Brain Function.

A modified extract from the seeds of an African berry tree. Improves cognitive and neurological function. Supports visual health and hearing. Delivers a clinically effective dose of vinpocetine

Vinpo-15 is vinpocetine (ethyl apovincamine), an alkaloid originally identified in periwinkle (Vinca minor). Vinpocetine helps support brain function and cognitive health.

Vinpocetine is a modified compound originally found in the periwinkle plant (Vinca minor) that helps support brain function and cognitive health. Like the well-known botanical, Ginkgo biloba, vinpocetine supports blood flow, oxygen and nutrient delivery to the brain; unlike ginkgo, it does so without reducing blood flow elsewhere in the body. Studies in red blood cells and damaged neurons show that vinpocetine directly increases ATP levels in these cells, supporting optimal brain energy levels. In addition, vinpocetine’s blood thinning effects are far less potent than those of ginkgo, making it a much safer compound. One study showed that vinpocetine helped reduce tinnitus and hearing loss after exposure to loud noises, and research suggests that it may also enhance circulation in the eyes.

Vinpo-15 is an excellent alternative for those who want the health benefits of Ginkgo biloba, but who are concerned about its blood thinning effects. Vinpo-15 is a good choice for those looking to support their memory and brain function with age, as well as those with a family history of stroke. Vinpo-15 may also improve eye health and tinnitus.

Supplement Facts:

Non-Medicinal Ingredients: microcrystalline cellulose. Capsule: hypromellose.

AOR guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.

References:

1. Afon’kin VIu, Dobretsov KG, Sipkin AV. [The new scheme of cavinton application to the treatment of chronic neurosensory loss of hearing]. Vestn Otorinolaringol. 2009;(6):69-70.
2. Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc. 1987 May;35(5):425-30.
3. Chukanova EI.  [Efficacy of cavinton in the treatment of patients with chronic blood flow insufficiency. Russian multicenter clinical-epidemiological program "CALIPSO"]. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(12):49-52.
4. Fischhof PK, Moslinger-Gehmayr R, Herrmann WM, et al. Therapeutic efficacy of vincamine in dementia. Neuropsychobiology. 1996;34(1):29-35.
5. Kahan A, Olah M. Use of ethyl apovincaminate in ophthalmological therapy. Arzneimittelforschung. 1976;26(10a):1969-72.
6. Kiss B, Karpati E. Mechanism of action of vinpocetine. Acta Pharm Hung. 1996 Sep;66(5):213-24.
7. Konopka W, Zalewski P, Olszewski J, et al. Treatment results of acoustic trauma. Otolaryngol Pol. 1997;51 Suppl 25:281-4.
8. Molnar P, Gaal L, Horvath C. The impairment of long-term potentiation in rats with medial septal lesion and its restoration by cognition enhancers. Neurobiology (Bp). 1994;2(3):255-66.
9. Nagy Z, Vargha P, Kovács L, Bönöczk P. Meta-analysis of Cavinton. Praxis. 1988 Sep; 7(9):63-8.
10. Pliushko DG, Sobko EG. Drug therapy of initial open-angle glaucoma. Oftalmol Zh. 1989;(2):72-4.
11. Subhan Z, Hindmarch I. Psychopharmaco-logical effects of vinpocetine in normal healthy volunteers. Eur J Clin Pharmacol. 1985;28(5):567-71.
12. Ueyoshi A, Ota K. Clinical appraisal of vinpocetine for the removal of intractable tumoral calcinosis in haemodialysis patients with renal failure. J Int Med Res. 1992 Sep;20(5):435-43.